Back to Search
ANIMESH PARDANANI, PHD, MBBS
PHD, MBBS
Hematology (Internal Medicine) Physician
NPI: 1700856804IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology & Oncology Physician
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
43004(MN)
Hematology (Internal Medicine) PhysicianPrimary
Internal Medicine — Hematology
Code: 207RH0000X
43004(MN)
Education
OTHER
Class of 1991
Research & Publications (20)
CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.
PMID 19295546·Leukemia·2009
4-observational
Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders.
PMID 18006699·Blood·2008
8-other
JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients.
PMID 18380991·Mayo Clin Proc·2008
4-observational
JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials.
PMID 17882282·Leukemia·2008
6-review
Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes.
PMID 17540852·Stem Cells·2007
8-other
Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera.
PMID 17597810·Leukemia·2007
8-other
TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.
PMID 17541402·Leukemia·2007
7-preclinical
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.
PMID 16868251·Blood·2006
8-other
Pathogenesis, clinical features, and treatment advances in mastocytosis.
PMID 16781490·Best Pract Res Clin Haematol·2006
6-review
FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature.
PMID 16406016·Leuk Res·2006
8-other
Systemic mastocytosis: bone marrow pathology, classification, and current therapies.
PMID 15995324·Acta Haematol·2005
6-review
Bone marrow mast cell immunophenotyping in adults with mast cell disease: a prospective study of 33 patients.
PMID 15203275·Leuk Res·2004
8-other
FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia.
PMID 15284118·Blood·2004
8-other
Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders.
PMID 15166033·Blood·2004
6-review
Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders.
PMID 15036941·Leuk Res·2004
6-review
Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine.
PMID 14654076·Leuk Res·2004
5-case
Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis.
PMID 12393530·Blood·2003
8-other
Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia.
PMID 12860006·Leuk Res·2003
5-case
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 200 1ST ST SW
ROCHESTER, MN 55905 - Phone
- (507) 284-2511
Quick Facts
- NPI
- 1700856804
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 35
- Publications
- 20
Are you this provider?
Claim Your Profile